只有BRCA突变的患者才应联合用药：雄激素受体通路抑制剂与PARP抑制剂治疗转移性去势抵抗性前列腺癌的适用性分析
Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
正在获取期刊数据...
发表日期:2024 Jul
作者:
DOI:10.1016/j.euf.2024.07.015
摘要
AI正在翻译并加载中文摘要...